细胞治疗的联盟和授权合约(2016年～2023年)

本报告提供全球生物製药企业的相关调查，提供各企业的细胞治疗相关联盟，开发，研究，授权合约之详细分析。

目录

摘要整理

第1章 简介

第2章 细胞治疗的交易趋势

• 简介
• 多年的细胞治疗的交易
• 最活跃的细胞治疗的交易商
• 细胞治疗的交易:各交易类型
• 细胞治疗的交易:各治疗领域
• 细胞治疗的交易:各产品部门
• 细胞治疗交易的交易条件
  • 细胞治疗的标题金额
  • 细胞治疗交易的预付款金
  • 细胞治疗交易的里程碑付款
  • 细胞治疗的特许权比率

第3章 主要细胞治疗的交易

• 简介
• 以金额为主前几名细胞治疗的交易

第4章 最活跃的细胞治疗的交易商

• 简介
• 最活跃的细胞治疗的交易商
• 最活跃的细胞治疗交易的企业简介

第5章 细胞治疗的契约成立名录

• 简介
• 细胞治疗的契约成立名录

第6章 细胞治疗的交易成立:各技术类型

• 交易名录
• 交易名录 - 细胞治疗的交易:各企业(A～Z)
• 交易名录 - 细胞治疗的交易:各交易类型
• 交易名录 - 细胞治疗的交易:各治疗领域
• 交易类型定义
• 关于Wildwood Ventures
• Current Partnering
• Current Agreements
• Current Partnering最近的报告标题

Description

Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 845 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cell therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cell therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cell Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cell therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Cell Therapy Collaboration and Licensing Deals includes:

• Trends in cell therapy dealmaking in the biopharma industry
• Directory of cell therapy deal records covering pharmaceutical and biotechnology
• The leading cell therapy deals by value
• Most active cell therapy licensing dealmakers
• Cell Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cell therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

• 2.1. Introduction
• 2.2. Cell therapy deals over the years
• 2.3. Most active cell therapy dealmakers
• 2.4. Cell therapy deals by deal type
• 2.5. Cell therapy deals by therapy area
• 2.6. Cell therapy deals by industry sector
• 2.7. Deal terms for cell therapy deals
  • 2.7.1 Cell therapy deals headline values
  • 2.7.2 Cell therapy deal upfront payments
  • 2.7.3 Cell therapy deal milestone payments
  • 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

• 3.1. Introduction
• 3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

• 4.1. Introduction
• 4.2. Most active cell therapy dealmakers
• 4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

• Deal directory
• Deal directory - Cell therapy deals by company A-Z
• Deal directory - Cell therapy deals by deal type
• Deal directory - Cell therapy deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Cell therapy deals since 2016
• Figure 2: Active cell therapy dealmaking activity - 2016 - 2023
• Figure 3: Cell therapy deals by deal type since 2016
• Figure 4: Cell therapy deals by therapy area since 2016
• Figure 5: Cell therapy deals by industry sector since 2016
• Figure 6: Cell therapy deals with a headline value
• Figure 7: Cell therapy deals with an upfront value
• Figure 8: Cell therapy deals with a milestone value
• Figure 9: Cell therapy deals with a royalty rate value
• Figure 10: Top cell therapy deals by value since 2016
• Figure 11: Most active cell therapy dealmakers 2016 - 2023
• Figure 12: Cell therapy deals by technology type since 2016